Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

CRNX Insider Trading

Crinetics Pharmaceuticals, Inc. | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Crinetics Pharmaceuticals, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Last 7 Days
$0
Buys
$0
Sells
Last 30 Days Trend
$0
Buys
$0
Sells

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2021-10-29 00:00 2021-10-27 Betz Stephen F. Officer - Chief Scientific Officer SELL $24.00 3,000 $71,991 183,883 -1.6%
2021-10-25 23:28 2021-10-21 Betz Stephen F. Officer - Chief Scientific Officer SELL $21.10 1,042 $21,984 186,883 -0.6%
2021-10-25 21:47 2021-10-25 PERCEPTIVE ADVISORS LLC 10% owner BUY $19.80 1,200,000 $23,760,000 5,163,517 +30.3%
2021-09-10 00:00 2021-09-08 Fust Matthew K Director OPT+S $25.50 6,046 $154,173 12,536 0.0%
2021-09-10 00:00 2021-09-07 Struthers Richard Scott Director, Officer - President & CEO SELL $25.00 30,000 $750,000 90,000 -25.0%
2021-07-28 03:00 2021-07-26 Fust Matthew K Director OPT+S $19.59 5,000 $97,950 12,536 0.0%
2021-07-21 00:00 2021-07-19 Fust Matthew K Director OPT+S $19.50 5,000 $97,500 12,536 0.0%
2021-07-14 00:00 2021-07-12 Fust Matthew K Director OPT+S $20.71 5,000 $103,550 12,536 0.0%
2021-04-09 16:00 2021-04-08 PERCEPTIVE ADVISORS LLC 10% owner BUY $16.44 304,136 $4,999,996 3,963,517 +8.3%
2020-12-05 00:59 2020-12-02 Struthers Richard Scott Director, Officer - President & CEO BUY $13.00 5,000 $65,000 4,000 +100.0%
2020-07-18 00:05 2020-07-15 Struthers Richard Scott Director, Officer - President & CEO SELL $14.88 35,000 $520,828 890,805 -3.8%
2020-04-20 15:30 2020-04-17 PERCEPTIVE ADVISORS LLC 10% owner BUY $14.00 1,071,428 $14,999,992 3,659,381 +41.4%
2020-04-18 01:38 2020-04-15 Vivo Capital VIII, LLC 10% owner SELL $15.45 330,598 $5,106,747 298,625 -52.5%
2020-04-08 02:27 2020-04-03 Vivo Capital VIII, LLC 10% owner SELL $13.81 306,115 $4,226,836 338,738 -47.5%
2020-03-12 00:12 2020-03-09 Vivo Capital VIII, LLC 10% owner SELL $19.50 528 $10,296 168,165 -0.3%
2020-02-12 04:00 2020-02-07 Vivo Capital VIII, LLC 10% owner SELL $21.66 13,460 $291,587 168,298 -7.4%
2020-02-07 03:22 2020-02-04 Vivo Capital VIII, LLC 10% owner SELL $22.80 13,460 $306,888 178,816 -7.0%
2020-02-01 04:00 2020-01-29 Vivo Capital VIII, LLC 10% owner SELL $22.07 26,920 $594,165 189,335 -12.4%
2019-12-19 02:32 2019-12-16 Fust Matthew K Director OPT+S $22.50 3,500 $78,750 12,536 0.0%
2019-06-26 02:03 2019-06-21 5AM Ventures IV, L.P. Other SELL $22.20 250,000 $5,550,000 94,489 -72.6%
2019-03-25 13:04 2019-03-20 Vivo Capital VIII, LLC 10% owner SELL $22.25 417,000 $9,278,250 210,373 -66.5%
2019-03-20 23:48 2019-03-18 5AM Ventures IV, L.P. 10% owner SELL $24.25 154,839 $3,754,954 104,489 -59.7%
2019-01-25 03:01 2019-01-22 5AM Ventures IV, L.P. 10% owner SELL $21.88 262,153 $5,734,597 129,483 -66.9%
2018-08-28 01:12 2018-07-18 PERCEPTIVE ADVISORS LLC Director, 10% owner BUY $18.87 707,648 $13,352,893 2,587,953 +37.6%
2018-07-21 02:02 2018-07-20 5AM Ventures IV, L.P. 10% owner BUY $17.00 115,000 $1,955,000 139,969 +460.6%
2018-07-21 00:19 2018-07-20 PERCEPTIVE ADVISORS LLC Director, 10% owner BUY $17.00 400,000 $6,800,000 2,280,305 +21.3%
2018-07-20 23:50 2018-07-20 Vivo Capital VIII, LLC 10% owner BUY $18.62 353,180 $6,575,435 294,357 +100.0%
2018-07-20 23:06 2018-07-20 Krasner Alan Seth Officer - Chief Medical Officer BUY $17.00 2,000 $34,000 2,000 +100.0%
SHOW ENTRIES
101-128 OF 128

How to Interpret $CRNX Trades

Not every insider transaction in Crinetics Pharmaceuticals, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CRNX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for CRNX

Insider activity data for Crinetics Pharmaceuticals, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CRNX, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.